Ursapharm was founded in 1974. It is located in Saarbrucken, an industrial town in southern Germany. 

For over 40 years, URSAPHARM has been systematically developing innovative pharmaceutical concepts into successful medicinal products and medical devices. Today, URSAPHARM is an international mid-sized family-run business, and with a broad product portfolio, it is one of Germany’s market leaders in ophthalmology. A wide variety of products in the general health care segment round off the URSAPHARM portfolio. URSAPHARM also operates as an efficient contract manufacturer, supplying partners worldwide with its expertise in the fields of development, production, quality control and quality assurance.

URSAPHARM manufactures eye drops, eye ointments, nasal drops and nasal sprays under the most stringent national and international quality standards. The wide range of dosage forms manufactured on URSAPHARM’s production lines also includes film-coated tablets and capsules.

The tolerability of the preparations, and thus the well-being of the patients, are central to product development at URSAPHARM. By eliminating potentially harmful preservatives from multiple-dose containers for eye drops or nasal spray/ nasal drops, URSAPHARM has become the first manufacturer to take a decisive step in enhancing patient safety and will consistently pursue this approach in future.

iCare provides eye doctors with the latest solutions for comprehensive screening, diagnostics and monitoring of glaucoma, diabetic retinopathy, and macular degeneration (AMD). Our product line includes handheld rebound tonometers, automated TrueColor imaging devices, and perimeters. 

iCare is the original developer of rebound technology for handheld tonometers. After decades of hard work, Finnish MD, Dr. Antti Kontiola, succeeded to find a new, easy, and patient-friendly method of measuring intraocular pressure (IOP). The original rebound method was clinically tested in cooperation with Helsinki University Eye Clinic.

iCare tonometers are fast, reliable, and accurate tools to help in the process of detecting and following-up glaucoma. Measurement of intraocular pressure does not require anesthetic drops, air puffs, or special skills. Several clinical studies show data obtained by iCare is comparable to the measurement results with the Goldmann Applanation Tonometer (GAT).

AZAD Pharma was established 20 years ago and is headquartered in Schaffhausen Switzerland. The company develops and offers generic APIs and Finished Products (FPs), targeting unique processes and formulations in order to circumvent patent barriers and provide customers the opportunity for early market entry.

Teams of experienced chemists, formulators and regulatory experts are responsible for assuring our products (and documentation) are of the highest quality, and that the requirements of all regulators are met.

AZAD`s offices are located in Armenia, Canada, China and Switzerland, facilitating access and support to clients in the Americas, Europe, Asia, Middle East and the CIS region.

Teajoon Pharm., founded in 1978, is a global pharmaceutical company accomplished in exporting aseptic eye drops to Europe for the first time in Korea. In addition, we are the specialty pharmaceutical company in ophthalmology, gastroenterology, and radiology. Teajoon Pharm.’s Yongin plant, which was built in October, 2005, became Korea’s first EU-GMP certified plant to produce qualified pharmaceutical products that export to Europe.

Teajoon Pharm. aims to improve the healthcare society based on our vision of “The company that perceives happiness of humanity”. Teajoon Pharm. has been participation in improving medical fields by awarding Teajoon’s medicine, ophthalmology thesis and service since 2002.

Teajoon Pharm. promises to challenge research-intensive trends, trying new changes based on innovative company, to develop a worldwide company capable of global competitiveness to satisfy clients’ needs.

Echo has  the accumulated experience and technical development over 30 years on composite

processing of various adhesive materials. 

Based on the application of those knowledge, Echo manufactures diagnostic medical device, “Strip Meniscometry Tube (SMTube)”, developed for a simple, accurate, swift and minimally-invasive assessment of tear meniscus volume. 

 The tear film stability is closely related to the tear volume. Thus, the tear volume is an important parameter to conduct tear-film-oriented-therapy properly, where the treatment of dry eye disease or the postoperative care for refractive and cataract surgeries are typical examples of such.

Other Business Lineup: 

Processing and production of tape products

Design and fabrication of labor-saving equipment

Development, design and fabrication of visual inspection system for PCB

HOYA Surgical Optics (HSO), belonging to HOYA Group, is headquartered in Singapore and is one of the world's leading manufacturers and suppliers of intraocular lenses, focusing on the development of intraocular lenses and their implantation systems. At present, HSO has developed a wide range of surgical optical products and innovative intraocular lens materials, including monofocal and astigmatic high-end intraocular lenses, which can be implanted into the eyes through small/micro incisions and also can provides additional retinal protection by offering filters that can block harmful blue light.

HSO is a global leader in preloaded intraocular lenses, and millions of preloaded intraocular lenses have been used by ophthalmologists worldwide. In China, HOYA preloaded intraocular lenses are widely used in renowned ophthalmic medical institutions.

Mingsight pharmaceuticals is an R & D enterprise committed to developing new drugs that can meet major clinical needs. The founder of the company has many years of experience in successfully developing and managing new drugs in international pharmaceutical giants. Mingsight pharmaceutical focuses on the research and development of a new generation of selective protein kinase C (PKC) inhibitor MS-553, which has been initially clinically validated in major diseases such as chronic lymphocytic leukemia and diabetic macular edema. It is a leading enterprise in the research and development of PKC inhibitors.

Compared with previous PKC inhibitors, MS-553 has made breakthroughs in target selectivity. Mingsight pharmaceutical carried out phase 1/2 clinical trials of chronic lymphocytic leukemia (CLL) at Ohio State University, University of Utah, University of Michigan, Columbia University and MD Anderson Cancer Center in the United States. Through the cooperation with Relin medicine, the clinical phase 1/2 trial of MS-553 in the treatment of diabetic macular edema was carried out in China. In addition, MS-553 is ready to enter phase II clinical trials for multiple autoimmune disease indications, and has been approved for several clinical trials for autoimmune disease indications in China and the United States. MS-553 has been clinically validated in multiple indications, showing outstanding preliminary efficacy, that is the Pipeline In a Product and is expected to become a First-in-Class product.

Mingsight pharmaceutical hopes to bring new drugs that can significantly improve the curative effect to patients with many major diseases as soon as possible.

Hubei Keyi Pharmaceutical Co., Ltd. is located in the East Lake High-tech Development Zone in Wuhan and is a national key high-tech enterprise under China Torch Program. It is now a subsidiary of China Meheco Group Co., Ltd. (Ticker Symbol: China Meheco; Stock Code: 60056). Since its establishment, Keyi Pharma has been adhering to technological innovation and marketing innovation, with six production lines for formulation products including lyophilized powder injection, tablets, capsules, creams, gels and granules, as well as API. The company has a professional academic promotion and marketing team, as well as a sales network covering the entire country.

Keyi Pharma took the lead in the research and development of domestic nucleoside antiviral drugs and has gradually formed its own characteristics in the development process over the years. The company has taken the lead in research, development, production, and sales of a series of antiviral drugs, such as Acyclovir, Ganciclovir, Penciclovir, Valacyclovir, and Imiquimod. It has now become an important backbone enterprise for the industrialization of antiviral drugs in China, integrating scientific research, production, and operation.

Founded on July 28, 1992, Shenzhen Wanhe Pharmaceutical Co., Ltd. (SZWH) has been designated as a National Level High-tech Enterprise, Shenzhen High-tech Enterprise, Guangdong Engineering Research Center for Orally Disintegrating ＆ Sustained / Controlled  Release Preparations, Guangdong Key Laboratory for Microecological Preparations，Guangdong Postdoctoral Innovation Practice Base, Shenzhen Engineering Research Center for Novel Oral Solid Preparations and Shenzhen Enterprise Technology Center.

SZWH has leading technologies in sustained/controlled-release ultra-micro pellet preparation and mouth disintegrating preparation, and has a specialized academic marketing team and abundant expert resources in the fields of digestion, liver and kidney diseases. In addition to conducting R&D on a Class I innovative drug DHMEQ, SZWH has also undertaken a number of key projects in strategic emerging industries for Guangdong province and Shenzhen city in recent years, and has achieved fruitful results. SZWH has independent intellectual property rights for its main products, and currently owns 61 patents. Since its establishment, SZWH has continually enhanced its production, marketing, R&D, and pharmacovigilance systems. As of now, SZWH’s products have been sold throughout China and exported to a number of countries in both Southeast Asia and Eastern Europe.

Established in 2012, Beijing Huonland Pharmaceutical Co., Ltd. is located in the Tongzhou Economic Development Zone of Beijing. It was founded by Beijing Northland Pharmaceutical Technology Co., Ltd. and Huons Co., Ltd.. The company specializes in the research and development, production, and sales of ophthalmic drugs.

The company has introduced an internationally advanced "Blow-Fill-Seal" fully automatic aseptic eye drop production line, which can produce single-dose and multi-dose eye drops. The production line has passed the 2010 version of GMP certification, and the current annual production capacity is 110 million units. The company provides safe, effective, and reliable products for ophthalmic clinical practice.

The company's overall business strategy is driven by both independent product sales and contract manufacture. The company uses advanced production equipment and a sound quality management system to provide CMO/CDMO services for eye drops that the varieties cover ophthalmic drugs for myopia, dry eye disease, anti-infection, anti-allergic, anti-inflammatory, glaucoma, corneal repair, and pupil dilation.